Nebivolol Levels and Effects while Breastfeeding

Summary of Use during Lactation

Because no information is available on the use of nebivolol during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

The excretion of beta-adrenergic blocking drugs into breastmilk is largely determined by their protein binding. Those with low binding are more extensively excreted into breastmilk.[1] Accumulation of the drugs in the infant is related to the excretion rate. With 98% protein binding and a relatively long half-life, nebivolol presents a moderate risk for accumulation in infants.

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Nebivolol Identification

Substance Name

CAS Registry Number

99200-09-6

Drug Class

Adrenergic beta-Antagonists

Antihypertensive Agents

Vasodilator Agents

Administrative Information

LactMed Record Number

891

Last Revision Date

20160707

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.